Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021 News provided by Share this article Share this article SAN FRANCISCO and SUZHOU, China, June 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase 1 study in Chinese patients with advanced solid tumors were released today at ...
Source: prnewswire.com
